Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
WALTHAM, Mass., April 25, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Leerink Boston Biopharma Bus Tour on Wednesday, May 10, 2017. Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, EVP and CFO of TESARO, will present at 1:00 PM ET and will answer questions from investors.
- The Bank of America Merrill Lynch 2017 Healthcare Conference at the Loews Hotel in Las Vegas, Nevada on Wednesday, May 17, 2017. Tim Pearson will participate in an analyst-led moderated Q&A at 3:00 PM PT and in meetings with investors.
A live webcast of the presentation at the Bank of America conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
